[8-K] ASP Isotopes Inc. Reports Material Event

Rhea-AI Filing Summary

ASP Isotopes Inc. reported business updates via Form 8-K. The company announced a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the United States. A press release with details is furnished as Exhibit 99.1.

Insights

Strategic operations analyst

Administrative disclosure of two strategic actions; terms not disclosed.

ASP Isotopes disclosed two moves: a supply agreement for enriched silicon-28 and a U.S. radiopharmacy acquisition. These actions point to upstream materials positioning and downstream healthcare footprint expansion.

Without disclosed pricing, size, or timing, the financial impact cannot be assessed from this excerpt. The attached Exhibit 99.1 is referenced for details, while select paragraphs are excluded from incorporation by reference.

0001921865false00019218652025-10-132025-10-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2025

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41555		87-2618235
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Pennsylvania Avenue NW, South Building, Suite 900 Washington, DC		20004
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 756-2245

 Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		ASPI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ 

Item 8.01. Other Events.

On October 13, 2025, ASP Isotopes Inc. (the “Company”) issued a press release announcing business updates, including a supply agreement for enriched silicon-28 and an acquisition of a radiopharmacy in the United States. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference, other than the seventh, tenth and eleventh paragraphs of the press release.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 13, 2025, of ASP Isotopes Inc. announcing business updates, including a supply agreement for enriched silicon-28 and an acquisition of a radiopharmacy in the United States.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASP ISOTOPES INC.
Date: October 14, 2025	By:	/s/ Donald G. Ainscow
	Name:	Donald G. Ainscow
	Title:	Executive Vice President, General Counsel and Secretary

3

FAQ

What did ASPI announce in this 8-K?

The company announced a supply agreement for enriched silicon-28 and an acquisition of a radiopharmacy in the United States.

Which document contains the detailed ASPI business updates?

Details are in the press release furnished as Exhibit 99.1.

Are all parts of the press release incorporated by reference?

All except the seventh, tenth and eleventh paragraphs are incorporated by reference.

What is ASPI’s trading symbol and exchange?

ASPI trades on The Nasdaq Stock Market LLC under the symbol ASPI.

Does this 8-K include financial statements?

It furnishes a press release as Exhibit 99.1 and lists the cover page interactive data file (Exhibit 104).